<DOC>
	<DOCNO>NCT00012090</DOCNO>
	<brief_summary>RATIONALE : Some tumor need growth factor produce body 's white blood cell keep grow . Goserelin may interfere growth factor may stop tumor grow . Bicalutamide may prevent androgen stimulate growth cancer cell . PURPOSE : Phase II trial study effectiveness goserelin plus bicalutamide treating patient refractory recurrent cancer ovary , fallopian tube , peritoneum .</brief_summary>
	<brief_title>Bicalutamide Goserelin Treating Patients With Cancer Ovary , Fallopian Tube , Peritoneum</brief_title>
	<detailed_description>OBJECTIVES : I . Determine time-to-treatment failure patient ovarian epithelial , fallopian tube , peritoneal carcinoma , second great remission , treat bicalutamide goserelin . II . Assess luteinizing hormone follicle-stimulating hormone suppression correlation serum vascular endothelial growth factor level , determine level related time treatment failure patient . III . Correlate presence absence androgen receptor tissue expression immunohistochemistry androgen receptor gene trinucleotide repeat length time treatment failure patient . OUTLINE : Patients receive oral bicalutamide daily goserelin subcutaneously every 4 week . Treatment continue absence unacceptable toxicity disease recurrence . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm epithelial carcinoma arise ovary , fallopian tube , peritoneum , second great remission Failed initial therapy persistent recurrent disease Cytoreductive surgery AND At least 1 platinumbased chemotherapy regimen No evidence disease within 4 month salvage chemotherapy CA125 le 35 U Negative physical exam No abdominal pelvic disease CT PATIENT CHARACTERISTICS : Age : Adult Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) SGOT le 2 time ULN Alkaline phosphatase less 2 time ULN Renal : Not specify Other : No active invasive malignancy No inability receive subcutaneous injection No inability tolerate oral medication PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No concurrent oral anticoagulant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>